193022-95-6

Upstream product

• 504-24-5 4-aminopyridine 
• 1262327-68-3 4-(2-(trimethylsilyl)ethylthio)phenol 
• 1262327-69-4 4-(4-(2-(trimethylsilyl)ethylthio)phenoxy)pyridine 
• 15854-87-2 4-iodopyridine 
• 637-89-8 4-sulfanylphenol 
• 102877-78-1 4-(4-pyridinyloxy)aniline 

Downstream Products

• 1262327-60-5 4-(4-pyridoxy)phenyl disulfide 

Relevant academic research and scientific papers

Synthesis of dihydroindolizines for potential photoinduced work function alteration

Seeking to immobilize photochromophores on metallic surfaces, we have synthesized four molecules which contain both a photoresponsive dihydroindolizine (DHI) core and a sulfur containing moiety, which allow for their assembly onto gold substrates. Sonogashira, Suzuki, or Ullmann couplings are employed to generate pyridines with pendant thioacetates (or disulfides). The pyridines are condensed with spiro[2-cyclopropene-1, 9′-[9H]fluorene]- 2, 3-dimethyl ester affording the targeted DHIs.

Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity

Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity.

Matrix metalloprotease inhibitors

The present invention relates to compounds of Formula I: STR1 that are matrix metalloprotease inhibitors, pharmaceutical compositions containing them, methods for their use and methods of preparing these compounds.

Matrix metalloprotease inhibitors

Compounds of the formula: wherein: n is0, 1 or 2; Y ishydroxy or XONH-, where X is hydrogen or lower alkyl; R1is hydrogen or lower alkyl; R2is hydrogen, lower alkyl, heteroalkyl, aryl, aralkyl, arylheteroalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl, heteroarylheteroalkyl, heterocyclo, heterocylo-lower alkyl, heterocyclo-lower heteroalkyl or -NR6R7, wherein: R6is hydrogen, lower alkyl, cycloalkyl or cycloalkylalkyl, aryl, heteroaryl and heteroaralkyl; R7is hydrogen, lower alkyl, cycloalkyl or cycloalkylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, -C(O)R8, -C(O)NR8R9, -SO2NR8R9, -SO2R10, aryloxycarbonyl, or alkoxycarbonyl; or R6and R7together with the nitrogen atom to which they are attached represent a heterocyclo group; wherein R8and R9are independently hydrogen, lower alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl or heteroalkyl; and R10is lower alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, heteroalkyl or heterocyclo; or R1and R2together with the carbon atom to which they are attached represent a cycloalkyl or heterocyclo group; R3ishydrogen, lower alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, heteroalkyl or lower alkoxy; R4ishydrogen, lower alkyl, cycloalkyl or cycloalkylalkyl; or R2and R3together with the carbons to which they are attached represent a cycloalkyl or heterocyclo group; or R3and R4together with the carbon to which they are attached represent a cycloalkyl or heterocyclo group; and R5islower alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroaryl, or heteroaralkyl; or pharmaceutically acceptable salts or esters thereof exhibit useful pharmacological properties, in particular for use as matrix metalloprotease inhibitors, particularly for interstitial collagenases.